Northern Trust Corp Amylyx Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

$586 Billion
Q2 2024

A detailed history of Northern Trust Corp transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 367,249 shares of AMLX stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

367,249

Previous 425,567 13.7%

Holding current value

$1.82 Million

Previous $1.21 Million 42.3%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.71 $94,475 - $158,041	-58,318 Reduced 13.7%	367,249 $697,000
Q1 2024 May 14, 2024	SELL	$2.71 - $19.57 $26,747 - $193,155	-9,870 Reduced 2.27%	425,567 $1.21 Million
Q4 2023 Feb 13, 2024	BUY	$12.07 - $18.46 $116,584 - $178,305	9,659 Added 2.27%	435,437 $6.41 Million
Q3 2023 Nov 13, 2023	SELL	$18.08 - $23.45 $1.08 Million - $1.4 Million	-59,640 Reduced 12.29%	425,778 $7.8 Million
Q2 2023 Aug 11, 2023	BUY	$20.98 - $31.42 $451,867 - $676,723	21,538 Added 4.64%	485,418 $10.5 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $1.9 Million - $2.81 Million	68,741 Added 17.4%	463,880 $13.6 Million
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $3.25 Million - $4.29 Million	109,331 Added 38.25%	395,139 $14.6 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $3.28 Million - $5.91 Million	191,267 Added 202.31%	285,808 $8.05 Million
Q2 2022 Aug 12, 2022	BUY	$6.85 - $19.93 $84,741 - $246,554	12,371 Added 15.06%	94,541 $1.82 Million
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $1.06 Million - $2.7 Million	82,170 New	82,170 $1.06 Million

Others Institutions Holding AMLX

# of Institutions

139

Shares Held

46.5M

Call Options Held

226K

Put Options Held

909K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Amylyx Pharmaceuticals, Inc. Transaction History